Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CLADIN- CLADribine and INnate immune response in multiple sclerosis - A phase IV prospective study.
Monif M, Sequeira RP, Muscat A, Stuckey S, Sanfilippo PG, Minh V, Loftus N, Voo V, Fazzolari K, Moss M, Maltby VE, Nguyen AL, Wesselingh R, Seery N, Nesbitt C, Baker J, Dwyer C, Taylor L, Rath L, Van der Walt A, Marriott M, Kalincik T, Lechner-Scott J, O'Brien TJ, Butzkueven H. Monif M, et al. Among authors: dwyer c. Clin Immunol. 2024 Aug;265:110304. doi: 10.1016/j.clim.2024.110304. Epub 2024 Jul 2. Clin Immunol. 2024. PMID: 38964633 Clinical Trial.
Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.
Seery N, Li V, Nguyen AL, Roos I, Buzzard KA, Atvars R, Taylor N, Tunnell K, Carey J, Dwyer C, Taylor HFL, Baker J, Marriott MP, Kilpatrick TJ, Kalincik T, Monif M. Seery N, et al. Among authors: dwyer c. Mult Scler Relat Disord. 2020 Nov;46:102516. doi: 10.1016/j.msard.2020.102516. Epub 2020 Sep 16. Mult Scler Relat Disord. 2020. PMID: 32957057 Free PMC article.
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study.
Seery N, Sharmin S, Li V, Nguyen AL, Meaton C, Atvars R, Taylor N, Tunnell K, Carey J, Marriott MP, Buzzard KA, Roos I, Dwyer C, Baker J, Taylor L, Spriggs K, Kilpatrick TJ, Kalincik T, Monif M. Seery N, et al. Among authors: dwyer c. CNS Drugs. 2021 Aug;35(8):907-918. doi: 10.1007/s40263-021-00810-3. Epub 2021 Apr 13. CNS Drugs. 2021. PMID: 33847902 Free PMC article.
High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients.
Dwyer CM, Jokubaitis VG, Stankovich J, Baker J, Haartsen J, Butzkueven H, Cartwright A, Shuey N, Fragoso YD, Rath L, Skibina O, Fryer K, Butler E, Coleman J, MacIntrye J, Macdonell R, van der Walt A. Dwyer CM, et al. Ther Adv Neurol Disord. 2021 Apr 16;14:1756286421998915. doi: 10.1177/1756286421998915. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33948117 Free PMC article.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group. Roos I, et al. JAMA Neurol. 2023 Aug 1;80(8):789-797. doi: 10.1001/jamaneurol.2023.1625. JAMA Neurol. 2023. PMID: 37307006 Free PMC article.
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. Kalincik T, et al. JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184. JAMA Neurol. 2023. PMID: 37437240 Free PMC article.
Neutropaenia complications from Ocrelizumab and Rituximab treatment.
Pang V, Seery N, Wesselingh R, Yeh W, Zhong M, Tan T, Dwyer C, Nesbitt C, Rath L, Perera D, Bridge F, Skibina O, Bosco JJ, Jokubaitis V, Marriott M, Butkueven H, Van Der Walt A, Massey J, Sutton I, Monif M. Pang V, et al. Among authors: dwyer c. Mult Scler Relat Disord. 2024 Jan;81:105147. doi: 10.1016/j.msard.2023.105147. Epub 2023 Nov 21. Mult Scler Relat Disord. 2024. PMID: 38043368 Free article.
HLA-DRB1*15:01 and the MERTK Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS.
Binder MD, Nwoke EC, Morwitch E, Dwyer C, Li V, Xavier A, Lea RA, Lechner-Scott J, Taylor BV, Ponsonby AL, Kilpatrick TJ; Ausimmune Investigator Group. Binder MD, et al. Among authors: dwyer c. Neurol Neuroimmunol Neuroinflamm. 2024 Mar;11(2):e200190. doi: 10.1212/NXI.0000000000200190. Epub 2023 Dec 27. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38150649 Free PMC article.
371 results